Pathogenesis of hypertension in renal failure: Role of the sympathetic nervous system and renal afferents

Clinical and Experimental Pharmacology and Physiology

Volumn 32, Issue 5-6, 2005, Pages 415-418

  Phillips, Jacqueline K ^a  

^a MURDOCH UNIVERSITY   (Australia)

Author keywords

Autonomic nervous system; Efferent; Muscle sympathetic nerve activity; Polycystic kidney disease; Renin angiotensin aldosterone system; Renovascular hypertension

Indexed keywords

ANGIOTENSIN; CATECHOLAMINE DERIVATIVE; SODIUM;

ADRENERGIC SYSTEM; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHEMORECEPTOR; CONFERENCE PAPER; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HYPERTENSION; HYPOTHALAMUS; KIDNEY; KIDNEY FAILURE; MECHANORECEPTOR; PATHOGENESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM BALANCE; SODIUM URINE LEVEL; SYMPATHETIC INNERVATION; SYMPATHETIC TONE;

AFFERENT PATHWAYS; ANIMALS; HUMANS; HYPERTENSION; KIDNEY; KIDNEY FAILURE; SYMPATHETIC NERVOUS SYSTEM;

EID: 20344368376     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2005.04204.x     Document Type: Conference Paper

References (50)

1. Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J. Am. Soc. Nephrol. 2003; 14: 3239-44.
2. Campese VM. A new model of neurogenic hypertension caused by renal injury: Pathophysiology and therapeutic implications. Clin. Exp. Nephrol. 2003; 7: 167-71.
3. Johansson M, Elam M, Rundqvist B et al. Increased sympathetic nerve activity in renovascular hypertension. Circulation 1999; 99: 2537-42.
4. Neumann J, Ligtenberg G, Klein IH, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: Pathogenesis, clinical relevance, and treatment. Kidney Int. 2004; 65: 1568-76.
5. Converse RL, Jacobsen TN, Toto RD et al. Sympathetic overactivity in patients with chronic renal failure. N. Engl. J. Med. 1992; 327: 1912-18.
6. Hausberg M, Kosch M, Harmelink P et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106: 1974-9.
7. Augustyniak RA, Tuncel M, Zhang W, Toto RD, Victor RG. Sympathetic overactivity as a cause of hypertension in chronic renal failure. J. Hypertens. 2002; 20: 3-9.
8. Campese VM. The kidney and the neurogenic control of blood pressure in renal disease. J. Nephrol. 2000; 13: 221-4.
9. Ciriello J, de Oliveira CV. Renal afferents and hypertension. Curr. Hypertens. Rep. 2002; 4: 136-42.
10. Barajas L, Liu L, Powers K. Anatomy of the renal innervation: Intrarenal aspects and ganglia of origin. Can. J. Physiol. Pharmacol. 1992; 70: 735-49.
11. Ritz E, Amann K, Fliser D. The sympathetic nervous system and the kidney: Its importance in renal diseases. Blood Press. 1998; Suppl. 3: 14-19.
12. Kopp UC, Olson LA, DiBona GF. Renorenal reflex responses to mechano- and chemoreceptor stimulation in the dog and rat. Am. J. Physiol. 1984; 246: F67-77.
13. DiBona GF, Kopp UC. Neural control of renal function. Physiol. Rev. 1997; 77: 75-197.
14. Granger JP, Alexander BT, Llinas M. Mechanisms of pressure natriuresis. Curr. Hypertens. Rep. 2002; 4: 152-9.
15. DiBona GF. Sympathetic nervous system and the kidney in hypertension. Curr. Opin. Nephrol. Hypertens. 2002; 11: 197-200.
16. Salem MM. Pathophysiology of hypertension in renal failure. Semin. Nephrol. 2002; 22: 17-26.
17. Martinez-Maldonado M. Hypertension in end-stage renal disease. Kidney Int. Suppl. 1998; 68: S67-72.
18. Endemann DH, Wolf K, Boeger CA, Riegger GA, Kramer BK. Adrenal aldosterone biosynthesis is elevated in a model of chronic renal failure: Role of local adrenal renin-angiotensin system. Nephron. Physiol. 2004; 97: 37-44.
19. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25: 878-82.
20. Adamczak M, Zeier M, Dikow R, Ritz E. Kidney and hypertension. Kidney Int. Suppl. 2002; 80: 62-7.
21. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J. Am. Soc. Nephrol. 2003; 14: 425-30.
22. Fink GD. Long-term sympatho-excitatory effect of angiotensin II: A mechanism of spontaneous and renovascular hypertension. Clin. Exp. Pharmacol. Physiol. 1997; 24: 91-5.
23. Nystrom HC, Jia J, Johansson M, Lambert G, Bergstrom G. Neurohormonal influences on maintenance and reversal of two-kidney one-clip renal hypertension. Acta Physiol. Scand. 2002; 175: 245-51.
24. Thomas L, Gasser B, Bousquet P, Monassier L. Hemodynamic and cardiac anti-hypertrophic actions of clonidine in Goldblatt one-kidney, one-clip rats. J. Cardiovasc. Pharmacol. 2003; 41: 203-9.
25. Katholi RE. Renal nerves in the pathogenesis of hypertension in experimental animals and humans. Am. J. Physiol. 1983; 245: F1-14.
26. Wyss JM, Aboukarsh N, Oparil S. Sensory denervation of the kidney attenuates renovascular hypertension in the rat. Am. J. Physiol. 1986; 250: H82-6.
27. Kopp UC, Buckley-Bleiler RL. Impaired renorenal reflexes in two-kidney, one clip hypertensive rats. Hypertension 1989; 14: 445-52.
28. Campese VM, Krol E. Neurogenic factors in renal hypertension. Curr. Hypertens. Rep. 2002; 4: 256-60.
29. Rahn KH, Barenbrock M, Hausberg M. The sympathetic nervous system in the pathogenesis of hypertension. J. Hypertens. 1999; 17 (Suppl. 3): S11-14.
30. Esler M, Kaye D. Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure. J. Auton. Nerv. Syst. 1998; 72: 210-19.
31. Gabow PA, Chapman AB, Johnson AM. Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int. 1990; 38: 1177-80.
32. Zoccali C, Mallamaci F, Parlongo S et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-9.
33. Cerasola G, Vecchi M, Mule G et al. Sympathetic activity and blood pressure pattern in autosomal dominant polycystic kidney disease hypertensives. Am. J. Nephrol. 1998; 18: 391-8.
34. Phillips JK, Rangan G, Hopwood D, McKitrick DJ. Characterisation of hypertension in a new model of PKD in rats. J. Hypertens. 2004; 22 (Suppl. 1): S157 (Abstract).
35. Ye S, Gamburd M, Mozayeni P, Koss M, Campese VM. A limited renal injury may cause a permanent form of neurogenic hypertension. Am. J. Hypertens. 1998; 11: 723-8.
36. Boero R, Pignataro A, Ferro M, Quarello F. Sympathetic nervous system and chronic renal failure. Clin. Exp. Hypertens. 2001; 23: 69-75.
37. Fitch GK, Weiss ML. Activation of renal afferent pathways following furosemide treatment. II. Effect of angiotensin blockade. Brain Res. 2000; 861: 377-89.
38. de Wardener HE. The hypothalamus and hypertension. Physiol. Rev. 2001; 81: 1599-658.
39. Rosas-Arellano MP, Solano-Flores LP, Ciriello I. c-Fos induction in spinal cord neurons after renal arterial or venous occlusion. Am. J. Physiol. 1999; 276: R120-7.
40. Solano-Flores LP, Rosas-Arellano MP, Ciriello J. Fos induction in central structures after afferent renal nerve stimulation. Brain Res. 1997; 753: 102-19.
41. Ciriello J, Rosas-Arellano MP, Solano-Flores LP. Induction of c-fos in forebrain circumventricular organs after renal artery stenosis. Brain Res. 2004; 995: 109-17.
42. Akine A, Montanaro M, Allen AM. Hypothalamic paraventricular nucleus inhibition decreases renal sympathetic nerve activity in hypertensive and normotensive rats. Auton. Neurosci. 2003; 108: 17-21.
43. Simon JK, Kasting NW, Ciriello J. Afferent renal nerve effects on plasma vasopressin and oxytocin in conscious rats. Am. J. Physiol. 1989; 256: R1240-4.
44. Chowdhary S, Townend JN. Nitric oxide and hypertension: Not just an endothelium derived relaxing factor! J. Hum. Hypertens. 2001; 15: 219-27.
45. Colombari E, Sato MA, Cravo SL, Bergamaschi CT, Campos RR, Lopes OU. Role of the medulla oblongata in hypertension. Hypertension 2001; 38: 549-54.
46. Krukoff TL, Gehlen F, Ganten D, Wagner J. Gene expression of brain nitric oxide synthase and soluble guanylyl cyclase in hypothalamus and medulla of two kidney, one clip hypertensive rats. Hypertension 1995; 26: 171-6.
47. Edwards MA, Loxley RA, Powers-Martin K et al. Unique levels of expression of N-methyl-D-aspartate receptor subunits and neuronal nitric oxide synthase in the rostral ventrolateral medulla of the spontaneously hypertensive rat. Mol. Brain Res. 2004; 129: 33-43.
48. Wang D, Strandgaard S. The pathogenesis of hypertension in autosomal dominant polycystic kidney disease. J Hypertens. 1997; 15: 925-33.
49. Al-Nimri MA, Komers R, Oyama TT, Subramanya AR, Lindsley JN, Anderson S. Endothelial-derived vasoactive mediators in polycystic kidney disease. Kidney Int. 2003; 63: 1776-84.
50. US Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda. 2004.